These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6980422)

  • 21. Effects of cystic fibrosis serum and cell culture medium on the mucociliary activity of the respiratory tract. An in vitro study in rabbits.
    Tegner H; Ceder O; Roomans GM; Kollberg H; Toremalm NG
    Acta Paediatr Scand; 1981 Sep; 70(5):629-33. PubMed ID: 7324909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biologic activities of cystic fibrosis serum. I. The effects of cystic fibrosis sera and calcium ionophore A 23187 on rabbit tracheal explants.
    Bogart BI
    Pediatr Res; 1977 Feb; 11(2):131-4. PubMed ID: 402628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaphylatoxins: C3a and C5a.
    Hugli TE; Müller-Eberhard HJ
    Adv Immunol; 1978; 26():1-53. PubMed ID: 358800
    [No Abstract]   [Full Text] [Related]  

  • 24. On the nature of the defect in cystic fibrosis.
    Conover JH; Conod EJ; Hirschhorn K
    Tex Rep Biol Med; 1976; 34(1):45-50. PubMed ID: 996792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition of ciliary activity in tracheal organ cultures by sera from children with cystic fibrosis and control subjects.
    Cherry JD; Roden VJ; Rejent AJ; Dorner RW
    J Pediatr; 1971 Dec; 79(6):937-42. PubMed ID: 5132306
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of an improved tracheal explant bioassay for the detection of the ciliary dyskinesia factor in cystic fibrosis serum.
    Gabridge MG; Bright MJ; Agee CC; Nickerson JM; Henderson NS
    Pediatr Res; 1979 Jan; 13(1):31-5. PubMed ID: 431999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciliary dyskinesia factors in cystic fibrosis and asthma.
    Wilson CB; Fudenberg HH
    Nature; 1977 Mar; 266(5601):463-4. PubMed ID: 67566
    [No Abstract]   [Full Text] [Related]  

  • 28. [Preparation of lyophilized reagents for determining the functional activity of complement C1, C2, C3, C4 and C5 components].
    Nikiforova TV; Kuznetsova NN; Vavilova LM
    Lab Delo; 1988; (3):28-31. PubMed ID: 2453712
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of complement anaphylatoxins in neutrophil arachidonic acid metabolism.
    Clancy RM; Hugli TE
    Prog Clin Biol Res; 1985; 199():173-84. PubMed ID: 2999821
    [No Abstract]   [Full Text] [Related]  

  • 30. Laser light-scattering spectroscopy: preliminary results on bioassay of cystic fibrosis factor(s).
    Verdugo P; Hinds TR; Vincenzi FF
    Pediatr Res; 1979 Feb; 13(2):131-5. PubMed ID: 432007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PMN C5a-receptor down regulation is not involved in recovery from C5a-induced neutropenia.
    Gardinali M; Hugli TE; Ward DM; Agostoni A
    ASAIO Trans; 1987; 33(3):482-8. PubMed ID: 3499922
    [No Abstract]   [Full Text] [Related]  

  • 32. C3a-induced lysosomal enzyme secretion from human neutrophils: lack of inhibition by f met-leu-phe antagonists and inhibition by arachidonic acid antagonists.
    Showell HJ; Glovsky MM; Ward PA
    Int Arch Allergy Appl Immunol; 1982; 67(3):227-32. PubMed ID: 6800960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biocompatibility of artificial organs: an overview.
    Henderson LW; Chenoweth D
    Blood Purif; 1987; 5(2-3):100-11. PubMed ID: 3304344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microvascular effects of anaphylatoxins C3a and C5a.
    Björk J; Hugli TE; Smedegård G
    J Immunol; 1985 Feb; 134(2):1115-9. PubMed ID: 3871207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo decomplementation of guinea pigs with cobra venom factor and anti-C3 serum: analysis of the requirement of C3 and C5 for the mediation of endotoxin-induced death.
    Drake WP; Pokorney DR; Kopyta LP; Mardiney MR
    Biomedicine; 1976 May; 25(3):91-4. PubMed ID: 949521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The biologic activities of cystic fibrosis serum. II. Ultrastructural aspects of the effect of cystic fibrosis sera and calcium ionophore A23187 on rabbit tracheal explants.
    Bogart BI; Conod EJ; Gaerlan PF; Conover J
    Pediatr Res; 1978 Jan; 12(1):15-24. PubMed ID: 347362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement activation and vascular injury in systemic lupus erythematosus.
    Abramson S; Belmont HM; Hopkins P; Buyon J; Winchester R; Weissmann G
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():43-6. PubMed ID: 2886660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research in cystic fibrosis (second of three parts).
    di Sant'Agnese PA; Davis PB
    N Engl J Med; 1976 Sep; 295(10):534-41. PubMed ID: 781536
    [No Abstract]   [Full Text] [Related]  

  • 39. Human platelet activation by C3a and C3a des-arg.
    Polley MJ; Nachman RL
    J Exp Med; 1983 Aug; 158(2):603-15. PubMed ID: 6604123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On cystic fibrosis factor (CFF) and its proposed influence on mucociliary function.
    Tegner H; Toremalm NG
    Rhinology; 1981 Sep; 19(3):115-20. PubMed ID: 7302469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.